Compositions and methods for the treatment of platinum-drug resistant cancer
US10517958B2 · kind B2 · utility
0Cited by
36References
50Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 4, 2017 |
| Grant date | Dec 31, 2019 |
| Priority date | — |
| Expiry date | Oct 4, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.